论文部分内容阅读
目前在我国1万余件药品专利中,80%为国外研究机构和企业所有,其中又有90%以上为发明专利。而我国企业生产的化学药品97%为仿制。对于刚刚参加国际市场游戏的中国本土药企来说,知识产权无疑是摆在他们面前的一道槛。那么如何跨过这道门槛,变不利之矛为护己之盾,几个问题值得探讨。一是目前本土医药企业知识产权保护的现状和存在的问题;二是如何借鉴国外的经验,发扬“拿来主义”;三是如何结合本土企业的实际,解决面临的问题,企业、政府以及法律界应该承当什么样的角色。为此,《法人》邀请政府部门官员、知识产权专家以及本土药企代表,进行了深入的探讨。
Currently in our country more than 10,000 pieces of drug patents, 80% of all foreign research institutions and enterprises, of which more than 90% for the invention of patents. 97% of our country’s chemical products are imitations. For Chinese local pharmaceutical companies who just participated in the international market games, intellectual property is undoubtedly a threshold before them. So how to cross this threshold, changing the spear to protect their own shield, a few questions worth exploring. First, the status quo and existing problems of IPR protection in local pharmaceutical companies; secondly, how to draw on the experience of other countries to promote “fetchingism”; third, how to solve the problems faced by enterprises in China, enterprises, government and law What kind of role should the community play? To this end, “legal person” invited government officials, intellectual property experts and representatives of local pharmaceutical companies conducted in-depth discussions.